3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
22
Phase 3
2
Phase 1
2
Phase NA
1
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Polycystic Ovary Syndrome
2
Pancreatic Neoplasms
2
Melanoma
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Infertility
1
Hereditary Sensory and Autonomic Neuropathies
1
Glioma
1
Chondrosarcoma
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Diseases
1
Interventions
Docetaxel
33
Prednisone
28
enzalutamide
19
Abiraterone Acetate
13
pembrolizumab
11
gallium 68 PSMA-11
9
Leuprolide
9
Radiotherapy
8
Pluvicto
8
Magnetic Resonance Spectroscopy
8
Nivolumab
7
Estramustine
7
abiraterone
6
Radiotherapy, Intensity-Modulated
6
Goserelin
6
Carboplatin
6
Biopsy
6
olaparib
5
cemiplimab
5
bicalutamide
5
Specimen Handling
5
Paclitaxel
5
Cyclophosphamide
5
temsirolimus
4
orteronel
4
darolutamide
4
cabazitaxel
4
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
4
Sirolimus
4
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Neoplasms
×
Metformin
×
Clear all
NCT04536805
2025-12-08
REPAIR
Institut Cancerologie de l'Ouest
Phase 1/2
Recruiting
44 enrolled